Literature DB >> 23253956

Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma.

Yao Zhu1, Hong-Kai Wang, Hai-Liang Zhang, Xu-Dong Yao, Shi-Lin Zhang, Bo Dai, Yi-Jun Shen, Xiao-Hang Liu, Liang-Ping Zhou, Ding-Wei Ye.   

Abstract

PURPOSE: Accurate assessment of disease characteristics is a prerequisite for treatment decision making regarding small renal masses. In this study we evaluate the association between visceral obesity and Fuhrman grade in patients with cT1a renal cell carcinoma.
MATERIALS AND METHODS: We retrospectively collected data on 186 patients with surgically treated cT1a renal cell carcinoma. Single slice computerized tomography was used to measure the area of visceral and subcutaneous adipose tissue. Visceral obesity was calculated as the proportion of visceral adipose tissue to overall adipose tissue. Other analyzed factors included clinical characteristics (age, gender, body mass index and tumor size) and anatomical features of the tumor defined by the R.E.N.A.L. nephrometry score. The association between predictors and high grade disease (Fuhrman grade III or IV) were assessed using logistic regression analyses.
RESULTS: A total of 47 (25.3%) tumors were classified as high grade. The percentage of visceral adipose tissue was higher in male participants but did not correlate with body mass index, age or tumor size. In univariate analyses the percentage of visceral adipose tissue and tumor size were significantly associated with higher Fuhrman grade. Multivariate analysis showed that the percentage of visceral adipose tissue (OR 1.06, p = 0.0018) and tumor size (OR 1.91, p = 0.047) were independent predictors of high grade cancer. Addition of the percentage of visceral adipose tissue to a model including clinical characteristics and anatomical features of the tumor remarkably improved its discriminatory ability (p = 0.0010).
CONCLUSIONS: Increased visceral obesity was found to be strongly associated with higher Fuhrman grade in patients with cT1a renal cell carcinoma. Further studies are needed to confirm these findings and discover the underlying biological mechanism.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23253956     DOI: 10.1016/j.juro.2012.09.030

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

1.  Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma.

Authors:  Roy Mano; A Ari Hakimi; Emily C Zabor; Marta A Bury; Olivio F Donati; Christoph A Karlo; Wassim M Bazzi; Helena Furberg; Paul Russo
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

2.  Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma.

Authors:  Zuohui Zhao; Jiaju Lu; Liping Han; Xiaoqing Wang; Quanzhan Man; Shuai Liu
Journal:  Tumour Biol       Date:  2015-12-29

3.  Elevated visceral obesity quantified by CT is associated with adverse postoperative outcome of laparoscopic radical nephrectomy for renal clear cell carcinoma patients.

Authors:  Tingshuai Zhai; Bocheng Zhang; Zhenan Qu; Chen Chen
Journal:  Int Urol Nephrol       Date:  2018-04-02       Impact factor: 2.370

4.  Influence of obesity on localized prostate cancer patients treated with radical prostatectomy.

Authors:  Yuan-Yuan Qu; Bo Dai; Yun-Yi Kong; Kun Chang; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Hai-Liang Zhang; Wei-Yi Yang
Journal:  Asian J Androl       Date:  2013-09-16       Impact factor: 3.285

Review 5.  Effects of obesity on immune responses to renal tumors.

Authors:  Vincent Chehval; Lyse A Norian
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

6.  Obesity as defined by waist circumference but not body mass index is associated with higher renal mass complexity.

Authors:  Laura A Bertrand; Lewis J Thomas; Peng Li; Claire M Buchta; Shannon K Boi; Rachael M Orlandella; James A Brown; Kenneth G Nepple; Lyse A Norian
Journal:  Urol Oncol       Date:  2017-08-07       Impact factor: 3.498

7.  Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series.

Authors:  Weijie Gu; Yao Zhu; Hongkai Wang; Hailiang Zhang; Guohai Shi; Xiaohang Liu; Dingwei Ye
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

Review 8.  Obesity and cancer progression: is there a role of fatty acid metabolism?

Authors:  Seher Balaban; Lisa S Lee; Mark Schreuder; Andrew J Hoy
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

Review 9.  Metabolic syndrome and renal cell carcinoma.

Authors:  Gui-Ming Zhang; Yao Zhu; Ding-Wei Ye
Journal:  World J Surg Oncol       Date:  2014-07-29       Impact factor: 2.754

Review 10.  Diet, obesity, and cancer progression: are adipocytes the link?

Authors:  Paul Toren; Benjamin C Mora; Vasundara Venkateswaran
Journal:  Lipid Insights       Date:  2013-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.